文献速递外周动脉疾病

药物涂层球囊血管成形术治疗复杂股腘动脉闭塞性疾病后再狭窄的危险因素

Risk Factors for Restenosis after Drug-coated Balloon Angioplasty for Complex Femoropopliteal Arterial Occlusive Disease.
PubMed 文献 · Ann Vasc Surg · 2018-08-15

单中心回顾性分析2013至2016年120例(137条肢体)接受药物涂层球囊治疗的股腘动脉病变,1年临床一期通畅率85.2%、2年65.3%,1年免于靶病变血运重建率93.0%、2年87.1%。危重肢体缺血(HR 5.80,95%CI 1.26-26.68,P=0.024)和高胆固醇血症(HR 4.66,95%CI 1.30-16.76,P=0.018)是再狭窄的独立预测因素。

要点

  • 药物涂层球囊治疗后1年临床一期通畅率85.2%,2年降至65.3%,1年后持续恶化。
  • 危重肢体缺血(HR 5.80,95%CI 1.26-26.68,P=0.024)为再狭窄独立预测因素。
  • 高胆固醇血症(HR 4.66,95%CI 1.30-16.76,P=0.018)为再狭窄独立预测因素。

核心结论

  • 药物涂层球囊治疗股腘动脉病变术后1年一期通畅率和免于靶病变血运重建率良好,但1年后一期通畅率持续恶化,提示晚期追赶现象。
  • 药物涂层球囊治疗后发生再狭窄的风险与危重肢体缺血和高胆固醇血症显著相关。

研究设计与样本

  • 单中心回顾性研究,纳入2013年至2016年因股腘动脉病变接受药物涂层球囊治疗的120例患者(137条肢体)。
  • 分析指标包括临床一期通畅率、靶病变血运重建(TLR)及再狭窄危险因素。

主要发现

  • 病变类型为原发病变80处、支架内再狭窄病变57处,平均病变长度22.2±11.6 cm。
  • 临床一期通畅率1年为85.2%、2年为65.3%;免于靶病变血运重建生存率1年为93.0%、2年为87.1%。
  • 危重肢体缺血(HR 5.80,95%CI 1.26-26.68,P=0.024)和高胆固醇血症(HR 4.66,95%CI 1.30-16.76,P=0.018)为再狭窄的独立预测因素。
  • 未使用西洛他唑和腘动脉受累显示再狭窄风险增加的趋势。

关键数值与推荐

  • 临床一期通畅率:1年85.2%,2年65.3%。
  • 免于靶病变血运重建生存率:1年93.0%,2年87.1%。
  • 危重肢体缺血:HR 5.80,95%CI 1.26-26.68,P=0.024。
  • 高胆固醇血症:HR 4.66,95%CI 1.30-16.76,P=0.018。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Currently, there exist limited data on patient outcomes following the use of drug-coated balloons (DCBs) to treat complex femoropopliteal arterial occlusive lesions. The aim of the this study is to investigate the outcomes of patient treated with DCBs and to identify the predictors of restenosis. METHODS: We retrospectively investigated medical records from 120 patients (137 limbs) treated with DCBs for femoropopliteal lesions at a single center between 2013 and 2016. Primary patency, target lesion revascularization (TLR), and risk factors of restenosis were analyzed. RESULTS: There were 80 de novo and 57 in-stent restenosis lesions. Mean lesion length was 22.2 ± 11.6 cm. The clinical primary patency was 85.2% at 1 year and 65.3% after 2 years. The TLR-free survival rate was 93.0% at 1 year and 87.1% after 2 years. Critical limb ischemia (CLI; hazard ratio [HR] 5.80, 95% confidence interval [CI] 1.26-26.68, P = 0.024) and hypercholesterolemia (HR 4.66, 95% CI 1.30-16.76, P = 0.018) were identified as independent predictors of restenosis. In addition, nonuse of cilostazol and popliteal artery involvement showed trends toward an increased risk of restenosis. CONCLUSIONS: Treatment with DCBs showed excellent primary patency and TLR-free survival at 1 year after the procedure. However, the primary patency continuously deteriorated beyond 1 year, suggesting a late catch-up phenomenon. The risk of restenosis after treatment with DCBs was significantly associated with CLI and hypercholesterolemia.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Roh JW, Ko YG, Ahn CM, et al. Risk Factors for Restenosis after Drug-coated Balloon Angioplasty for Complex Femoropopliteal Arterial Occlusive Disease. Ann Vasc Surg. 2018. PMID: 30118857. doi:10.1016/j.avsg.2018.06.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。